Findell Capital Management LLC Grows Stock Position in Abivax SA Sponsored ADR $ABVX

Findell Capital Management LLC increased its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 20.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,000 shares of the company’s stock after acquiring an additional 8,000 shares during the quarter. Abivax comprises approximately 1.9% of Findell Capital Management LLC’s holdings, making the stock its 11th biggest position. Findell Capital Management LLC owned about 0.06% of Abivax worth $6,473,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its holdings in Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Abivax by 661.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after acquiring an additional 344 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in Abivax in the 4th quarter worth approximately $61,000. WPG Advisers LLC increased its holdings in Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after acquiring an additional 253 shares in the last quarter. Finally, Union Bancaire Privee UBP SA purchased a new stake in Abivax in the 4th quarter worth approximately $67,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Price Performance

ABVX stock opened at $100.15 on Thursday. Abivax SA Sponsored ADR has a 1-year low of $5.69 and a 1-year high of $148.83. The company has a market capitalization of $7.99 billion, a price-to-earnings ratio of -19.22 and a beta of 0.69. The business has a 50 day simple moving average of $114.81 and a two-hundred day simple moving average of $118.49.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. Sell-side analysts anticipate that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Wolfe Research set a $136.00 target price on shares of Abivax in a report on Wednesday, June 3rd. BTIG Research reissued a “buy” rating and issued a $150.00 target price on shares of Abivax in a report on Tuesday. Wedbush raised shares of Abivax from an “underperform” rating to a “neutral” rating and reduced their target price for the stock from $110.00 to $90.00 in a report on Tuesday, June 2nd. Finally, Citizens Jmp increased their target price on shares of Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 2nd. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $130.08.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.